Male gender and younger age were identified as risk factors for IOP elevation after dexamethasone implant (Ozurdex, Allergan) treatment in retinal vein occlusion (RVO) in a recent subset analysis, but the elevated IOP did not seem to affect improvement in visual acuity or anatomic outcomes evaluated with optical coherence tomography (OCT), according to Dr Michael Singer. 

The analysis was performed to evaluate potential risk factors associated with IOP elevation after dexamethasone implant treatment and to compare the visual acuity and anatomic outcomes between patients with and without IOP elevation. It was conducted on patients who had received dexamethasone treatment in the two identical sham-controlled trials that made up the GENEVA study. This population included 298 patients with elevated IOP after single treatment or re-treatment and 535 patients without IOP elevation. 

Dr Singer did not take part in the subset analysis but commented on the work from his perspective as a leading investigator and clinician who has extensive experience with the dexamethasone intravitreal implant. 

Gender was the only other significant factor to emerge from the analysis. Males composed 67.8% of the group with elevated IOP but 43.2% of the group without (p < 0.001). 

"If there are better ways to predict who is at risk or when they're at risk, it might decrease some of the apprehension that retina specialists have about using steroids," Dr Singer said. 

Male gender, younger age related to IOP elevation after RVO treatment, study finds